November 27, 2023
The Japanese health ministry on November 24 approved a batch of medicines for additional indications, including Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) and Takeda Pharmaceutical’s blood cancer drug Adcetris (brentuximab vedotin). Opdivo is now newly indicated for the treatment of...read more